Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Current Assets (2016 - 2025)

Spero Therapeutics' Current Assets history spans 10 years, with the latest figure at $67.3 million for Q4 2025.

  • For Q4 2025, Current Assets fell 37.28% year-over-year to $67.3 million; the TTM value through Dec 2025 reached $67.3 million, down 37.28%, while the annual FY2025 figure was $67.3 million, 37.28% down from the prior year.
  • Current Assets reached $67.3 million in Q4 2025 per SPRO's latest filing, up from $52.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $157.9 million in Q4 2021 to a low of $52.0 million in Q2 2022.
  • Average Current Assets over 5 years is $102.8 million, with a median of $106.8 million recorded in 2021.
  • Peak YoY movement for Current Assets: surged 93.28% in 2023, then plummeted 60.25% in 2025.
  • A 5-year view of Current Assets shows it stood at $157.9 million in 2021, then fell by 28.06% to $113.6 million in 2022, then rose by 15.53% to $131.2 million in 2023, then dropped by 18.24% to $107.3 million in 2024, then plummeted by 37.28% to $67.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Current Assets are $67.3 million (Q4 2025), $52.3 million (Q3 2025), and $59.4 million (Q2 2025).